MP74-16 DEVELOPMENT OF A PRACTICAL ANIMAL MODEL FOR HUMAN SPERMATOGONIAL STEM CELL TRANSPLANTATION

probenecid but did not reach statistical significance (18 2.6% vs. 22 3.7%, p1⁄40.19, Figure 1A). The most pronounced improvement was in the grade of sperm motility. Rapid linear motility increased significantly after 4 weeks of treatment (5.0 1.3% vs. 16 3.2%, p < 0.005, Figure 1B), and continued after the cessation of treatment (5.0 1.3% vs. 15 8.3%, p < 0.005, Figure 1B). Sperm concentrations remained normal throughout the course of the study. The medication was well-tolerated by all patients. CONCLUSIONS: This is the first study to report improved sperm motility from an oral medication in men with spinal cord injury. Planned placebo-controlled trials will determine optimal dosage regimens. Probenecid holds promise as a simple, effective therapy for low sperm motility in this severely affected group of patients.